It’s been an eventful week on the pipeline front with companies like Biogen (BIIB – Analyst Report), Prothena (PRTA – Snapshot Report) and Vertex (VRTX – Analyst Report) coming out with data. Meanwhile, Gilead (GILD – Analyst Report) was back in the news once again due to its hepatitis C virus (HCV) franchise.Recap of the Week’s Most Important Stories1. Hopes […]
Gilead Sciences’ (NASDAQ: GILD) blockbuster launches of the hepatitis C drugs Sovaldi and Harvoni resulted in its revenue jumping 122% in 2014, but with Gilead Sciences facing tough comparisons this year, these three big-cap biotech stocks may be in better positions to see their shares climb in 2015http://www.fool.com/investing/general/2015/03/01/3-big-cap-biotechs-that-could-trounce-gilead-scien.aspx
Source:
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
See which stocks […]
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year.If your portfolio could use some exposure to healthcare and biotechs, join the Fool’s Michael Douglass and Todd Campbell, along with special guest Kristine Harjes, to learn more about three promising stocks in the […]
Biotechnology’s mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them — but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there may be opportunities to discover emerging biotech companies with promising pipelines that could send their shares significantly higher in 2015. Ophthotech Corporation […]
Source: ;Flickr user VastateparksstaffWhen to sell a winning stock is one of the toughest questions for investors to answer. Selling a stock that is reaching for new highs might be the right decision sometimes, but other times it might mean getting out of a long-haul opportunity too early. With that in mind, we asked three Motley Fool analysts to tell […]
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and rough trading in between. Encouraging industry trends, increasing merger and acquisition activities, expansion into emerging markets and ever-increasing health care spending led the sector to easily outperform the broader U.S. equity markets.Though lofty valuations and regulatory concerns did bring in some pain […]
